Evofem Biosciences, Inc. EVFM
Set alert
0.01 USD 0.00 0.00%
As of Nov 2, 3:50 PM ET
0.006 Day range 0.0066
0.001 52-week range 0.014
- YTD
- -40.00%
- 1 year
- -40.00%
- Open
- 0.0066
- Prev close
- 0.006
- Mkt cap
- 795.18K
- Vol
- 14.13K
- Avg vol
- 167.65K
- EPS
- -0.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.006
- High
- 0.0066
- Forward P/E
- -0.48
- Beta
- -1.68
- Short ratio
- 0.19
- Inst. own
- 9.67%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.74126
- 200-d avg
- 3.61
- 1y target
- 11.05
30m chart
Built from the cached five-day intraday bars.
Signals (6)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2:10 PM | 17 hours ago |
| SMA: Bullish | Nov 2, 12:40 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 12:40 PM | 18 hours ago |
| MACD: Buy Signal | Nov 2, 12:40 PM | 18 hours ago |
| SMA: Bearish | Oct 30, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:00 PM | 3 days ago |
Analyst view
Consensus: buy
Buy
Price target (mean) 11.05 +184066.7% upside
Now 0.006
- Target (low)
- 0.75
- Target (mean)
- 11.05
- Target (high)
- 45.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 5
- 2 months ago 5
- 3 months ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.44 | -0.68 – -0.21 | -7.20 | +93.9% | 8.70M | +156.6% | 2 |
| Next quarter | -0.44 | -0.74 – -0.15 | -4.95 | +91.1% | 11.00M | +208.1% | 2 |
| Current year | -3.41 | -3.90 – -2.93 | -23.70 | +85.6% | 30.57M | +271.7% | 2 |
| Next year | -0.67 | -1.40 – -0.29 | -3.41 | +80.4% | 64.54M | +111.1% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Jul 15, 2022 | Morgan Stanley | Maintained | — | Underweight |
| Jun 2, 2022 | Laidlaw & Co. | Initiated | — | Buy |
| May 25, 2022 | Piper Sandler | Maintained | — | Overweight |
| May 11, 2022 | Morgan Stanley | Maintained | — | Underweight |
| May 10, 2022 | Morgan Stanley | Maintained | — | Underweight |
| Apr 12, 2022 | Morgan Stanley | Maintained | — | Underweight |
| Mar 4, 2022 | Morgan Stanley | Maintained | — | Underweight |
| Nov 16, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Oct 21, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Oct 14, 2021 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Aug 12, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Jun 7, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 8, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Oct 2, 2020 | Stifel | Initiated | — | Buy |
| Aug 20, 2020 | Morgan Stanley | Initiated | — | Equal-Weight |
| Jun 9, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Jun 8, 2020 | Piper Sandler | Initiated | — | Overweight |
| May 27, 2020 | Oppenheimer | Maintained | — | Outperform |
| Dec 11, 2019 | H.C. Wainwright | Reiterated | — | Buy |
| Sep 26, 2018 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jun 27, 2018 | RBC Capital | Initiated | — | Outperform |
| Jun 18, 2018 | Oppenheimer | Initiated | — | Outperform |
| Mar 19, 2018 | H.C. Wainwright | Initiated | — | Buy |